TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17. September 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
05. September 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
TransCode Therapeutics, Inc. Announces Closing of Public Offering
24. Juli 2024 16:05 ET
|
TransCode Therapeutics, Inc.
Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
22. Juli 2024 22:30 ET
|
TransCode Therapeutics, Inc.
Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
22. Juli 2024 16:07 ET
|
TransCode Therapeutics, Inc.
Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
10. Juni 2024 07:00 ET
|
TransCode Therapeutics, Inc.
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15. April 2024 09:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors